Investigation of Naltrexone for Pathological Gambling
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The investigators plan to investigate the safety, tolerability, and efficacy of the opioid
antagonist naltrexone in Pathological Gambling. We hypothesize that naltrexone will be
superior to placebo in reducing gambling urges and behavior, when combined with adjuvant
non-pharmacological treatment as usual.